Tumor-associated neoexpression of the pS2 peptide and MUC5AC mucin in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder

Histology and Histopathology

Volumn 23, Issue 5, 2008, Pages 539-548

  Kunze, E ^a   Krassenkova, I ^a   Fayyazi, A ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Pforzheim Hospital   (Germany)

Author keywords

Adenocarcinomas; Immunohistochemistry; MUC5AC mucin; pS2 peptide; Signet ring cell carcinomas; Tumor suppressors; Urinary bladder

Indexed keywords

MUCIN; MUCIN 5AC; TFF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; BLADDER; BLADDER TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HISTOLOGY; HUMAN; METABOLISM; PATHOLOGY; SIGNET RING CARCINOMA; UROTHELIUM;

ADENOCARCINOMA; CARCINOMA, SIGNET RING CELL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MUCINS; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 40349113354     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Albarracin C.T., Jafri J., Montag A.G., Hart J. and Kuan S.-F. (2000). Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinomas. Human Pathol. 31, 672-677.
2. Bara J., Nardelli J., Gadenne C., Prade M. and Burtin P. (1984). Differences in the expression of mucus-associated antigens between proximal and distal human colon adenocarcinomas. Br. J. Cancer 49, 495-501.
3. Corica F.A., Husmann D.A., Churchill B.M., Young R.H., Pacelli A., Lopez-Beltran A. and Bostwick D.G. (1997). Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow up. Urology 50, 427-431.
4. Henry J.A., Bennett M.K., Piggott N.H., Levett D.L., May F.E.B. and Westly B.R. (1991). Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br. J. Cancer 64, 677-682.
5. Hermeking H., Lengauer C., Polyak K., He T.C., Zhang L., Thiagalingam S., Kinzler K.W. and Vogelstein B. (1997). 14-3-3 sigma is a pS2-regulated inhibitor of G2/M progression. Mol. Cell. 1, 3-11.
6. Ho J.J., Han S.W., Pan P.L., Deng G., Kuan S.F. and Kim Y.S. (2003). Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells. Int. J. Oncol. 22, 273-279.
7. Ito Y., Yoshida H., Nakano K., Kobayashi K., Yokozawa T., Hirai K., Matsuura N., Kakudo K., Kuma K., Miyauchi A. (2002). Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyreoid. Br. J. Cancer 86, 912-916.
8. Kunze E. (1998). Formale Pathogenese des Harnblasenkarzinoms. In: Diagnostik und Therapie des Harnblasenkarzinoms. Bichler K.H., Wilbert D., Wechsel H.W. and Strohmaier W.L. (eds). Einhorn-Presse Verlag. Reinbeck, Germany. pp 14-42.
9. Kunze E. (1998). Histogenesis of nonurothelial carcinomas in the human and rat urinary bladder. Exp. Toxicol. Pathol. 50, 341-355.
10. Kunze E. and Francksen B. (2002). Histogenesis of nonurothelial carcinomas of the urinary bladder from pre-existent transitional cell carcinomas. A histopathological and immunohistochemical study. Urol. Res. 30, 66-78.
11. Kunze E. and Schlott T. (2007). High frequency of promoter methylation of the 14-3-3 sigma and CAGE-1 genes, but lack of hyper-methylation of the caveolin-1 gene in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder. Int. J. Mol. Med. 20, 557-563.
12. Kunze E., Francksen B. and Schulz H. (2001). Expression of MUC5AC apomucin in transitional cell carcinomas of the urinary bladder and ist possible role in the development of mucus-secreting adenocarcinomas. Virchows Arch. 439, 609-615.
13. Kunze E., von Bonin F., Werner C., Wendt M. and Schlott T. (2006). Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of alu elements. Int. J. Mol. Med. 17, 3-13.
14. Kunze E., Wendt M. and Schlott T. (2006). Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas. Int. J. Mol. Med. 18, 547-557.
15. Lyun Y., Song S.-Y. and Ahn G. (2002). Expression of maspin in pancreatic neoplasms: application of maspin immunohistochemistry to the differential diagnosis. Appl. Immunohistochem. Mol. Morphol. 10, 62-66.
16. Maass N., Teffner M., Rösel F., Pawaresch R., Jonat W., Nagasaki K. and Rudolph P. (2001). Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. J. Pathol. 195, 321-326.
17. Mathelin C., Tomasetto C. and Rio M.-C (2005). Le facteur en trèfle 1 (pS2/TFF1), un peptide aux multiples facettes. Bull. Cancer 92, 773-781.
18. Müller R. (2004). Crosstalk of oncogenic and prostanoid signalling pathways. J. Cancer Res. Clin. Oncol. 130, 429-444.
19. Ohshio G., Suwa H., Kawaguchi Y., Imamura M., Yamoaka Y., Yamabe H., Matsumoto M., Yoshioka H., Hashimoto Y. and Takeda H. (2000). Differential expression of human spasmolytic polypeptide (trefoil factor family-2) in pancreatic carcinomas, ampullary carcinomas, and mucin-producing tumors of the pancreas. Dig. Dis. Sci. 45, 659-664.
20. Pemberton P.A., Tipton A.R., Pavloff N., Smith J., Erickson J.R., Mouchabeck Z.M. and Kiefer M.C. (1997). Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J. Histochem. Cytochem. 45, 1697-1706.
21. Pinto-de-Sousa J., Reis C.A., David L., Pimenta A. and Cardoso-de-Oliviera M. (2004). MUC5B expression in gastric carcinomas: relationship with clinico-pathological parameters and with expression of mucins MUC1, MUC2, MUC5AC and MUC6. Virchows Arch. 444, 224-230.
22. Potempa J., Korzus E. and Travis J. (1994). The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269, 15957-15960.
23. Poulsom R. and Wright N.A. (1993). Trefoil peptides: a newly recognized family of epithelial mucin-associated molecules. Am. J. Physiol. 265, G205-G213.
24. Razani B., Woodman S.E. and Lisanti M.R. (2002). Caveolae: from cell biology to animal physiology. Pharmacological Rev. 54, 431-467.
25. Reis C.A., David L., Nielsen P.H., Clausen H., Mirgorodskaya K., Roepstorf P. and Sobrinho-Simões M. (1997). Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody. Int. J. Cancer 74, 112-121.
26. Ristimäki A., Honkanen N., Jankälä H., Sipponen P. and Härkönen M. (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57, 1276-1280.
27. Sada K., Takano T., Yanagi S. and Yamamura H. (2001). Structure and function of Syk protein-tyrosine kinase. J. Biochem. 130, 177-186.
28. Sager R., Sheng S., Pemberton P. and Hendrix M.J.C. (1996). Maspin: a tumor suppressing serpin. Curr. Top. Microbiol. Immunol. 213, 51-64.
29. Sands B.E. and Podolsky D.K. (1996). The trefoil peptide family. Annu. Rev. Physiol. 58, 253-273.
30. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Makai S., Asai K., Kimura S., Kato H., Kondo M. and Hla T. (1995). Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55, 3785-3789.
31. Saukkonen K., Nieminen O., van Rees B., Vilkki S., Härkönen M., Juhola M., Mecklin J.-P., Sipponen P. and Ristimäki A. (2001). Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin. Cancer Res. 7, 1923-1931.
32. Simpson L. and Parsons R. (2001). PTEN: life as a tumor suppressor. Exp. Cell. Res. 264, 29-41.
33. Song S.Y., Lee S.K., Kim D.H., Son H.J., Kim H.J., Lim Y.J., Lee W.Y., Chun H.-K. and Rhee J.C. (2002). Expression of maspin in colon cancers. Its relationship with p53 expression and microvessel density. Dig. Dis. Sci. 47, 1831-1835.
34. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J. and Koki A. (2000). COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89, 2637-2645.
35. Sung M.-T., Lopez-Beltran A., Eble J.N., Mac Lennan G.T., Tan P.-H, Montironi R., Jones T.D., Ulbright T.M., Blair J.E. and Cheng L. (2006). Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod. Pathol. 19, 1395-1401.
36. Taupin D., Pedersen J., Familari M., Cook G., Yeomans N. and Giraud A.S. (2001). Angmented intestinal trefoil factor (TFF3) and loss of pS2 (TFF3) expression precedes metaplastic differentiation of gastric epithelium. Lab. Invest. 81, 397-408.
37. Theisinger B., Welter C., Seitz G., Rio M.-C., Lathe R., Chambon P. and Blin N. (1991). Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma. Eur. J. Cancer 27, 770-773.
38. Tomasetto C., Masson R., Linares J.-L., Wendling C., Lefebvre O., Chenard M.-P. and Rio M.-C. (2000). pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterology 118, 70-80.
39. Van de Bovenkamp J.H.B., Korteland-van Male A.M., Warson C., Büller H.A., Einerhand A.W.C., Ectors N.L.E. and Dekker J. (2003). Gastric-type mucin and TFF-peptide expression in Barrett's oesophagus is disturbed during increased expression of MUC2. Histopathology 42, 555-565.
40. Wiechen K., Diatchenko L., Agoulnik A., Scharff K.M., Schober H., Arlt K., Zhumabayeva B., Siebert P.D., Dietel M., Schäfer R. and Sers C. (2001). Caveolin-1 is down-regulated in human ovarian carcinomas and acts as a candidate tumor suppressor gene. Am. J. Pathol. 159, 1635-1643.
41. Williams C.S., Mann M. and Dubois R.N. (1999). The role of cyclooxygenases in inflammation, cancer and development. Oncogene 18, 7908-7916.